Summary
- Profile Type
- Technology request
- POD Reference
- TRFR20250109022
- Term of Validity
- 9 January 2025 - 9 January 2026
- Company's Country
- France
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- Germany
- Netherlands
- Austria
- Belgium
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- French biotechnology company specializing in the medical applications of magnetosomes—magnetic nanoparticles synthesized by magnetotactic bacteria. Their primary focus is developing innovative cancer treatments utilizing these biologically produced nanoparticles.
- Full Description
-
Novel magnetosome based therapy for prostate cancer
One in 8 men will be diagnosed with prostate cancer (PCa) during their lifetime. However, despite PCa’s high prevalence, current treatments lack specificity, often causing side effects. Moreover, despite the high five-year survival rates of low to low-intermediate PCa patients (74% of all newly diagnosed PCa cases), recurrence remains a concern (40%). Focal therapies are sought as less invasive alternatives, targeting specific lesions while preserving healthy tissue. There is, therefore, a pressing need for novel focal approaches such as NANOBEAM to improve treatment outcomes and reduce adverse effects associated with whole-gland therapies, particularly for intermediate to high grade PCa cases.
Objective: Gather preclinical data to develop an innovative, cost-effective patient-friendly focal therapy that combines naturally-produced-iron-oxide nanoparticles (magnetosomes) and photothermal therapy (PTT) to address the challenges of current localised prostate cancer (PCa) treatments.
Main actions: Further develop and optimize protocol for magnetosome + PTT treatment through:
a) Toxicity assessment of magnetosomes and heating source
b) Magnetosome formation (lyophilisation, coating etc…)
c) Clinical trial organization with doctors specialized in prostate cancer treatment
d) Regulatory matters
e) Fabrication of heating source (ultrasound or laser)
f) Study of immune mechanisms involved in the treatment - Advantages and Innovations
- Following regulatory manufacturing of the two medical devices involved in the treatment (magnetosomes + laser) and assessment of their preclinical efficacy and safety, NANOBEAM will lead to the preparation and realisation (post-project) of a clinical trial.
- Technical Specification or Expertise Sought
-
Laser/ultrasound developer:
• Development of Precision Laser/ultrasound Systems
• Integration with Nanoparticle Therapies
• Regulatory Compliance and Manufacturing
Toxicity assessment:
• Toxicity studies of nanoparticles (magnetosomes) and heating sources (laser or ultrasound)
Fundamental studies of the mechanisms involved in the treatment
• Study of immune mechanisms involved in the treament
Artificial intelligence software developer
• Optimizing treatment parameters
• Personalizing therapy
• Advancing integration - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
Laser/ultrasound developer:
• Development of Precision Laser/ultrasound Systems
• Integration with Nanoparticle Therapies
• Regulatory Compliance and Manufacturing
Toxicity assessment:
• Toxicity studies of nanoparticles (magnetosomes) and heating sources (laser or ultrasound)
Fundamental studies of the mechanisms involved in the treatment
• Study of immune mechanisms involved in the treament
Artificial intelligence software developer
• Optimizing treatment parameters
• Personalizing therapy
• Advancing integration - Type and Size of Partner
- University
- SME 11-49
- SME <=10
- Other
- R&D Institution
- Type of partnership
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001003 - Cytology, Cancerology, Oncology
- Market keywords
- 05007007 - Other medical/health related (not elsewhere classified)
- 02007012 - Medical/health software
- Sector Groups Involved
- Health
- Targeted countries
- Germany
- Netherlands
- Austria
- Belgium